Business
GE HealthCare Enters an Agreement to Distribute Flyrcado Through CDL Nuclear Technologies Group, a Leading Provider of Cardiac PET Imaging Equipment and Services in the U.S.
GE HealthCare’s agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado. Through their
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nGE HealthCare’s agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado.\n\n\n\nThrough their nearly 225 U.S. customers, CDL and CardioNavix support more than 220,000 cardiac PET procedures annually.\n\n\n\nThis agreement builds the capabilities needed to support Flyrcado’s growth in outpatient cardiac PET imaging by pairing CardioNavix’s comprehensive program setup, workflow, and clinical and operations support with GE HealthCare’s contract manufacturing organization (CMO) network to accelerate site enablement.\n\n\n\n ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado™ (flurpiridaz F18) injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.\n\n\nAround six million myocardial perfusion imaging (MPI) procedures are performed each year in the U.S.1 Within that total, PET MPI represents roughly five to ten percent today2, and is increasingly utilized by U.S. cardiology practices.3 By strengthening delivery in office-based care, this collaboration is expected to accelerate adoption of Flyrcado, which in the multi-center international Phase III AURORA trial demonstrated higher diagnostic efficacy versus SPECT MPI for detecting coronary artery disease.4\n\n\n“This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care,” said Eric Ruedinger, vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada. “CDL Nuclear Technologies is a trusted name in private cardiology and nuclear imaging, and today’s announcement underscores the confidence both organizations have in Flyrcado’s potential. This agreement helps establish the foundation needed to support GE HealthCare’s vision for Flyrcado’s growt...